Biopharmaceutical Sector Leads the Way in Clinical Trial Data Sharing

18 March 2015

Bill Chin / The Pharmaceutical Research and Manufacturers of America (PhRMA)

Effective and responsible sharing of clinical trial data continues to expand scientific discourse and discovery, as we have chronicled here on the Catalyst.

Clinical-Trials-Data-SharingThrough the PhRMA-EFPIA Principles for Responsible Clinical Trial Data Sharing, the industry has made a firm commitment to publicize its research findings and created numerous avenues for qualified researchers to access this data.

Member companies such as Pfizer, Johnson & Johnson and GSK, among others, have robust data sharing mechanisms and most recently Astellas announced its participation in the independent online data hub ClinicalStudyDataRequest.com.

Recently, a New England Journal of Medicine study examined the reporting of clinical trial results for trials registered on Clinicaltrials.gov. The research covered the period between January 1, 2008, and August 31, 2012 and found that industry supported trials had the highest rate of results reporting, outpacing the reporting of National Institutes of Health (NIH) trials and other government or academic institution-funded trials.

It is important to note that the timeframe of this study predates the PhRMA-EFPIA Principles, so it is safe to conclude that even greater reporting of results is occurring today. Under the Principles, PhRMA member companies made the following commitments:

The ongoing sharing of information among government regulators, the academic and medical communities, physicians and the public improves patient health and informs our understanding of disease and potential treatments. The biopharmaceutical sector is proud of its track record of cooperation and looks forward to continuing our collaborative work of researching new medicines to meet patient needs around the world.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more